Vigilant Biosciences Selects Cardinal Health as Global Third Party Logistics Provider for OncAlert® Oral Cancer Product Line

Vigilant Biosciences Selects Cardinal Health as Global Third Party Logistics Provider for OncAlert® Oral Cancer Product Line November 18, 2015 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it has selected Cardinal Health, Inc., a leading healthcare

Cancer Detection Tool Earns CE Mark

Cancer Detection Tool Earns CE Mark November 18, 2015 The OncAlert Oral Cancer CD44/Total Protein LAB Test from Vigilant Biosciences now has the CE Mark, which means it has been approved for distribution and marketing in the 28 countries of the European Union (EU) as well as in Norway, Iceland, Liechtenstein, and Switzerland. Also known

Vigilant Biosciences Announces Distribution Agreements for OncAlert™ Oral Cancer Product Line for Czech Republic and Slovakia, Israel and Baltic Region

Vigilant Biosciences Announces Distribution Agreements for OncAlert™ Oral Cancer Product Line for Czech Republic and Slovakia, Israel and Baltic Region November 17, 2015 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today three exclusive multi-year distribution agreements for sales

Vigilant Biosciences Receives CE Mark for OncAlert™ Oral Cancer LAB Test to Aid in Diagnosis of Oral Cancer

Vigilant Biosciences Receives CE Mark for OncAlert™ Oral Cancer LAB Test to Aid in Diagnosis of Oral Cancer November 16, 2015 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it has CE Marked its OncAlert™ Oral Cancer

Vigilant Biosciences Approved to Market Oral Cancer Diagnosis Test in Europe

Vigilant Biosciences Approved to Market Oral Cancer Diagnosis Test in Europe November 16, 2015 Vigilant Biosciences, which develops solutions that aid in the early detection and intervention of cancer, announced Monday that it has CE Marked its OncAlert LAB Assay for oral cancer risk. CE Marking allows Vigilant Biosciences to market the product in the

Fort Lauderdale Diagnostics Tech Company Expands into European Markets

Fort Lauderdale Diagnostics Tech Company Expands into European Markets November 16, 2015 A Fort Lauderdale medical diagnostics technology company is expanding its European footprint after receiving an important approval from the European Union. Vigilant Biosciences said Monday it had received a so-called CE Mark for its oral cancer diagnostics test, which is also used in

Prescription for Economy: Healthcare Startup Energy

Prescription for Economy: Healthcare Startup Energy November 1, 2015 South Florida’s history of healthcare entrepreneurship has received a shot of new startup energy, and some business leaders see it as the prescription for a healthier local economy. Consider these developments: Startupbootcamp, Europe’s largest accelerator that is expanding globally, will announce Monday that it is bringing

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev C